Aptose Biosciences Statistics
Share Statistics
Aptose Biosciences has 2.55M
shares outstanding. The number of shares has increased by 3.36%
in one year.
| Shares Outstanding | 2.55M |
| Shares Change (YoY) | 3.36% |
| Shares Change (QoQ) | 9.12% |
| Owned by Institutions (%) | 0.11% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 818 |
| FTD / Avg. Volume | 0.36% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -185.81 and the forward
PE ratio is null.
Aptose Biosciences's PEG ratio is
1.87.
| PE Ratio | -185.81 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | 0.7 |
| PB Ratio | -1040.08 |
| P/FCF Ratio | -131.32 |
| PEG Ratio | 1.87 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Aptose Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.14,
with a Debt / Equity ratio of -0.14.
| Current Ratio | 2.14 |
| Quick Ratio | 2.14 |
| Debt / Equity | -0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-726,571.43 |
| Employee Count | 35 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -95.33% in the
last 52 weeks. The beta is 1.13, so Aptose Biosciences's
price volatility has been higher than the market average.
| Beta | 1.13 |
| 52-Week Price Change | -95.33% |
| 50-Day Moving Average | 3.47 |
| 200-Day Moving Average | 9.08 |
| Relative Strength Index (RSI) | 42.5 |
| Average Volume (20 Days) | 225,970 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | n/a |
| Net Income | -25.43M |
| EBITDA | n/a |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.04 |
Full Income StatementBalance Sheet
The company has 6.15M in cash and 621K in
debt, giving a net cash position of 5.53M.
| Cash & Cash Equivalents | 6.15M |
| Total Debt | 621K |
| Net Cash | 5.53M |
| Retained Earnings | -540.97M |
| Total Assets | 10.13M |
| Working Capital | 5.07M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -35.98M
and capital expenditures -5K, giving a free cash flow of -35.98M.
| Operating Cash Flow | -35.98M |
| Capital Expenditures | -5K |
| Free Cash Flow | -35.98M |
| FCF Per Share | -0.05 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
